Artwork

Content provided by Joel Nowak Cancer ABCs. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Nowak Cancer ABCs or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

How a Drug Gets Developed and Tested

30:09
 
Distribuie
 

Manage episode 211230951 series 2381686
Content provided by Joel Nowak Cancer ABCs. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Nowak Cancer ABCs or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Joel T Nowak interviews Dr. Maryanne Sadar, who has developed a novel drug target, an investigational treatment, that is a first in class hormone therapy operating on the N Terminal Domain of the androgen receptor. The investigational treatment, Epi-506, is being tested on men with advanced, metastatic prostate cancer.

Dr. Sadar describes how the drug target was first identified then how it was tested in cell lines, then animals and now in humans. She also describes the process of having to form a new corporation, Essa, to raise the funds and the expertise to conduct the clinical trial.

Epi-506 is currently in a first in humans, phase I, dose escalation trial is being conducted in both Canada and the United States. Dr. Sadar also discusses how a man with castrate resistant prostate cancer could join the trial.

Dr. Sadar‘s career as a human cancer researcher began before there were many other women in cancer research. She shared some of her experiences being a female pioneer in medical and cancer research. She also shared her very personal reason in her decision-making process to become a cancer researcher.

Dr. Sadar ends the podcast on a positive and very upbeat message to all Cancer Thrivers.

Read a Transcript of this Podcast

Support the show
  continue reading

24 episoade

Artwork
iconDistribuie
 
Manage episode 211230951 series 2381686
Content provided by Joel Nowak Cancer ABCs. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Nowak Cancer ABCs or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Joel T Nowak interviews Dr. Maryanne Sadar, who has developed a novel drug target, an investigational treatment, that is a first in class hormone therapy operating on the N Terminal Domain of the androgen receptor. The investigational treatment, Epi-506, is being tested on men with advanced, metastatic prostate cancer.

Dr. Sadar describes how the drug target was first identified then how it was tested in cell lines, then animals and now in humans. She also describes the process of having to form a new corporation, Essa, to raise the funds and the expertise to conduct the clinical trial.

Epi-506 is currently in a first in humans, phase I, dose escalation trial is being conducted in both Canada and the United States. Dr. Sadar also discusses how a man with castrate resistant prostate cancer could join the trial.

Dr. Sadar‘s career as a human cancer researcher began before there were many other women in cancer research. She shared some of her experiences being a female pioneer in medical and cancer research. She also shared her very personal reason in her decision-making process to become a cancer researcher.

Dr. Sadar ends the podcast on a positive and very upbeat message to all Cancer Thrivers.

Read a Transcript of this Podcast

Support the show
  continue reading

24 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință